Plain-English translation of NCT06764680 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications: trifluridine and tipiracil hydrochloride, , and sintilimab. Some participants will also receive targeted radiation therapy to specific tumors. The study is designed for people with advanced colorectal cancer that has progressed after at least two previous treatment attempts.
Current third-line treatments for advanced colorectal cancer have very limited effectiveness, extending survival by only 1–2 months. Researchers believe that combining these three medications—which work in different ways to fight cancer—may work better together than existing options, and adding radiation to targeted tumor sites might improve results even further.
You likely qualify if…
You likely don't qualify if…
You will take the three-drug medication combination by mouth as part of your regular treatment. Depending on which group you're assigned to, you may also receive targeted radiation therapy to specific tumor sites. Throughout the study, you'll have regular check-ups with imaging scans and blood tests to monitor how the treatment is working. You may also be asked to provide a tumor tissue sample or biopsy to help researchers understand your cancer better.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China